Development of a Combination Therapy for Prostate Cancer by Targeting Stat3 and HIF-1alpha
Final rept. 1 Jul 2010-30 Jun 2013
BAYLOR COLL OF MEDICINE HOUSTON TX
Pagination or Media Count:
It is becoming increasingly evident that improving the cure rate of many cancers will require treatment regimens hit more than one validated tumor targets. Developing an anti-cancer agent that targets two oncorproteins simultaneously is a promising strategy for accomplishing this goal. It would be expected to promote drug efficacy, reduce therapy-resistant without introducting additional toxic side effects. Recently, we have identified TEL03 from Chinese medicinal herb significantly inhibits activations of HIF-1alpha2alpha and phosphorylated Stat3 p-Stat3, and blocks the expression of their down-regulated oncogenes e.g. Bcl2, VEGF, Glut1, and others in cancer cells. TEL03 also dramatically suppressed the growth of prostate, breast and pancreatic tumors in xenograft models. Our previous studies provided evidence that targeting both HIF-1alpha and Stat3 together could improve tumor response to either agent alone, and reduce drug resistance and treatment failure.
- Medicine and Medical Research